BTIG analyst Timothy Chiang started Sarepta Therapeutics with a Buy rating and $120 price target. The company is the leader in the Duchenne muscular dystrophy space with its Exondys 51 estimated to generate sales of $300M in 2018, and its "extensive pipeline" of RNA-splicing product candidates, Chiang tells investors in a research note. While the stock is up 78% year-to-date, there is the potential for further upside as investors get additional visibility on Sarepta's gene therapy and phosphorodiamidate morpholino oligomer programs, the analyst contends.